Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10‐year follow‐up

Abstract

monotherapy or combined androgen blockade. They were followed until death, loss to follow-up, or until the end of the observation period (31 March 2004). We analysed all cases in each study as a single population, and compared Study 1 with Study 2. RESULTSThe mean patient ages were 67.2 years in Study 1 and 75.7 years in Study 2. During a median of 10.4 years of follow-up, 20 men in Study 1 and 17 in Study 2 died from prostate cancer, and 21 men in Study 1 and 50 in Study 2 died from other causes. In Study 1, the 10-year overall survival rate was 73% and the 10-year cause-specific survival rate was 86%, vs 41% and 78% in Study 2. Overall survival curves were similar to expected survival curves in both studies. There was no significant difference between studies in cause-specific survival. CONCLUSIONSThe progression of prostate cancer was retarded by primary hormone therapy in men with localized or locally advanced prostate cancer. With primary hormone therapy or prostatectomy, the men had a life-expectancy similar to that of the normal population. KEYWORDSlocalized, locally advanced prostate cancer, primary hormone therapy, LHRH agonist, survival OBJECTIVETo evaluate the efficacy of primary hormone therapy for localized or locally advanced prostate cancer, by analysing the 10-year survival rates for men with localized or locally advanced prostate cancer treated with primary hormone therapy or prostatectomy. PATIENTS AND METHODSBetween February 1993 and March 1995, men with T1b, T1c or T2-3 N0M0 prostate cancer were enrolled. In all, 176 men who had a prostatectomy were assigned to Study 1 and were given adjuvant luteinizing hormonereleasing hormone (LHRH) agonist; 151 men who did not have a prostatectomy were assigned to Study 2 and had LHRH agonist

Expression of Pituitary Tumor Transforming Gene 1 is an Independent Factor of Poor Prognosis in Localized or Locally Advanced Prostate Cancer Cases Receiving Hormone Therapy

“…In 2002, Labrie et al (2002) reported the efficacy of hormonal therapy for localized or locally advanced prostate cancer. In 2006, Akaza et al (2006) further confirmed the usefulness of PADT for localized or locally advanced prostate cancer by analyzing the 10-year survival rates for men with localized or locally advanced prostate cancer treated with PADT or prostatectomy. However, some patients who receive PADT, if followed long enough, will develop evidence of resistance and progression.…”

Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective

“…Akaza et al 8 reported that overall survival rate of patients with localized or locally advanced prostate cancer treated with primary hormonal therapy was equivalent to life expectancy of age-matched subjects in the healthy population. Before Akaza's report, Egawa et al 9 had already reported that primary hormonal therapy was as effective as radical prostatectomy with regard to disease-specific survival rate in localized prostate cancer.…”

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

“…In terms of clinically localized prostate cancer, Labrie et al reported that approximately 80% of stage B prostate cancer could be controlled for long periods with PADT, 16 and recent analyses of practice patterns showed that many patients with localized cancer treated conservatively receive PADT rather than local treatment or active surveillance/watchful waiting. 17,18 Nevertheless, there have been no reports of instruments to predict outcomes for any population of previously untreated patients initiating PADT until the publication of the J-CAPRA derivation paper. 8 J-CAPRA was developed by analysis of a large database of a variety of patients undergoing PADT in Japan, and should be useful for clinical application to predict PADT in patients with not only advanced disease, but also localized cancer.…”